Loading
A phase 3 trial of Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil and Ixabepilone in Breast cancer, run by UNICANCER, completed.
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer is a phase 3 interventional study registered as NCT00630032 by UNICANCER, with 762 participants recorded, started 2007-09 and reaching its primary completion in 2017-06. Interventions recorded: cyclophosphamide, Docetaxel, epirubicin hydrochloride, fluorouracil, ixabepilone. Conditions recorded: Breast Cancer.
Linked to the drug Ixabepilone because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
762 enrolled.
95% CI 74.53 to 82.73; Figures from the ClinicalTrials.gov results section (first posted 2021-03-16), not from a publication · 95% CI 79.06 to 86.87
Source95% CI 83.13 to 90.03; Figures from the ClinicalTrials.gov results section (first posted 2021-03-16), not from a publication · 95% CI 83.64 to 90.66
SourceShares Ixabepilone, Breast cancer (all types) and the tag pipeline.
Shares Epirubicin, Fluorouracil (5-FU), Docetaxel, Cyclophosphamide and the tag pipeline.
Shares Epirubicin, Fluorouracil (5-FU), Docetaxel, Cyclophosphamide and the tag pipeline.
Shares Epirubicin, Fluorouracil (5-FU), Docetaxel, Cyclophosphamide and the tag pipeline.
Shares Docetaxel, Cyclophosphamide, Breast cancer (all types) and the tag pipeline.
Shares Epirubicin, Docetaxel and the tag pipeline.
Shares Ixabepilone and the tag pipeline.